Ibandronate is an aminobisphosphonate that targets bone and inhibits osteoclasts. It is one of the most potent bisphosphonates currently under clinical investigation in metabolic bone disease and osteoporosis. In animal models ibandronate is 2, 10, 50 and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively, without any impairment of mineralization. Subcutaneous administration is as effective as intravenous administration, oral activity is 100 times lower. Tumor-related bone destruction of either humoral or metastatic origin is dramatically decreased. Bone loss and reduction in bone strength due to cessation of ovarian function is prevented by > 1 μg/kg/day subcutaneously. The total dose rather than the treatment schedule seems to be important for efficacy. Studies on bone quality following long-term treatment demonstrated normal bone without any signs of deterioration.

Keywords:
Ibandronate, Bisphosphonates, Hypercalcemia of malignancy, Tumor osteolysis, Bone metastases, Osteoporosis
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.